Cidara Therapeutics (NASDAQ:CDTX) is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives to address serious infections. Its innovative pipeline includes lead programs aimed at treating fungal infections, leveraging its proprietary Cloudbreak platform to develop fungicidal agents. Additionally, Cidara is engaged in developing antiviral conjugates through its proprietary technology, aiming to combat challenging viral diseases. With a mission to revolutionize the treatment of infectious diseases and improve patient outcomes, Cidara is dedicated to advancing its pipeline of therapeutics through clinical development to address the unmet needs in infectious disease therapy.